The capacity problem in nuclear medicine and why you should care
Demand for nuclear medicine is growing rapidly, driven by new opportunities in theranostics, neurology, and cardiology. Yet many departments struggle to keep pace, facing longer waiting lists, rising tracer costs, and increasing pressure on capacity. This whitepaper explores the cost of inaction and the clinical, operational, and financial benefits available to departments that act now.
What's inside this ebook?
A practical, evidence-based guide for nuclear medicine department heads, medical directors, and procurement decision-makers who need to make the case for AI investment, or understand why others are making it.
The structural forces driving PET volume growth, from FDG oncology and PSMA imaging to theranostics and neurology, and why most departments are already at capacity before the next wave arrives.
Foregone revenue from unscheduled patients. Avoidable tracer spend. Staff retention costs. Capital expenditure that arrives sooner than it needs to. A framework for quantifying what staying still actually costs.
A new digital scanner costs millions and takes 18 months to procure. AI-enhanced image reconstruction costs less than a scanner upgrade and is operational in a day. A clear-eyed comparison of the options.
At 15 percent annual growth, a department that defers action for two years is not facing the same problem it faces today. It is facing a larger version of it. The strategic case for acting before the demand curve outpaces your ability to respond.
.png)
.png)
